Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash & Current Investments: 2022-2025

Historic Cash & Current Investments for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $2.9 million.

  • Corvus Pharmaceuticals' Cash & Current Investments fell 38.74% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.3 million, marking a year-over-year decrease of 20.96%. This contributed to the annual value of $8.7 million for FY2024, which is 30.74% down from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Cash & Current Investments stood at $2.9 million for Q3 2025, which was down 80.48% from $14.7 million recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Cash & Current Investments peaked at $31.5 million during Q1 2022, and registered a low of $2.9 million during Q3 2025.
  • Moreover, its 3-year median value for Cash & Current Investments was $8.7 million (2024), whereas its average is $9.8 million.
  • The largest annual percentage gain for Corvus Pharmaceuticals' Cash & Current Investments in the last 5 years was 93.80% (2024), contrasted with its biggest fall of 76.72% (2024).
  • Corvus Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $13.2 million in 2022, then declined by 4.10% to $12.6 million in 2023, then slumped by 30.74% to $8.7 million in 2024, then crashed by 38.74% to $2.9 million in 2025.
  • Its Cash & Current Investments stands at $2.9 million for Q3 2025, versus $14.7 million for Q2 2025 and $5.0 million for Q1 2025.